

Figure 1. Temporal trends in sildenafil usage by hospital discharges and all-cause crude mortality in children.

Our investigation shows that sildenafil use has increased over the study period. Although we note a temporally associated decrease in mortality, this certainly does not imply that sildenafil use is the cause of this decrease. Rather, the decrease in mortality noted may be due to a variety of reasons, including use in lower-risk populations, different dosing regimens of sildenafil, and concomitant use (or not) of other therapeutic agents. Further studies, with careful attention to study design so that they are adequately powered to detect differences in mortality as an outcome, are needed to better understand the role of sildenafil either as monotherapy or in conjunction with other therapies.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Adnan T. Bhutta, M.B.B.S.
Brandon Beam, J.D.
Parthak Prodhan, M.D.
University of Arkansas for Medical Sciences
Little Rock, Arkansas
and
Arkansas Children's Hospital
Little Rock, Arkansas

References

1. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension [accessed 2012 Dec 13]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm
2. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, *et al*. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. *Circulation* 2012;125:324–334.
3. Barst RJ, Layton GR, Konourina I, Richardson H, Beghetti M, Ivy DD. STARTS-2: Long-term survival with oral sildenafil monotherapy in treatment-naïve patients with pediatric pulmonary arterial hypertension [abstract]. *Eur Heart J* 2012;33:979.
4. Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, Wessel DL, Steinhorn R, Adatia I, Hanna B, *et al*.; Pediatric Pulmonary Hypertension Network (PPHNet). Implications of the FDA warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. *Am J Respir Crit Care Med* 2013; 187:572–575.
5. Child Health Corporation of America. Owner hospitals. 2012 [accessed 2013 Jan 25]. Available from: chca.com/owner_hospitals/index.html
6. European Medicines Agency. EPAR summary for the public: Revatio [accessed 2012 Dec 13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000638/WC500055835.pdf

Erratum: The Emerging Role of the Ubiquitin Proteasome in Pulmonary Biology and Disease

There are errors in the figures and accompanying legends in the article by Weathington and colleagues, published in the September 1, 2013, issue of the *Journal* (1). In the schematic Figures 1 and 2, the enzymes E1 and E2 were mislabeled as ligases. In addition, the figure legends also referred to E1 and E2 enzymes as ligases; however, E1 enzymes should have been termed "activating enzymes," and E2 enzymes, "conjugating enzymes." For the convenience of our readers, a corrected version of the article replaced the previous version on November 8, 2013.

Reference

1. Weathington NM, Sznajder JI, Mallampalli RK. The emerging role of the ubiquitin proteasome in pulmonary biology and disease. *Am J Respir Crit Care Med* 2013;188:530–537.

Erratum: Molecular Characterization of a Superoxide-Generating NAD(P)H Oxidase in the Ventilatory Muscles

The authors have noticed an error in their article published in the February 1, 2002, issue of the *Journal*. The surname of the first author of the article was misspelled on the manuscript they submitted for publication. It appears incorrectly as Javesghani; however, the correct form of the name is Javeshghani.

Reference

1. Javeshghani D, Magder SA, Barreiro E, Quinn MT, Hussain SNA. Molecular characterization of a superoxide-generating NAD(P)H oxidase in the ventilatory muscles. *Am J Respir Crit Care Med* 2002;165:412–418.